Challenges and New Approaches in GIST Management (Debulking, Multimodality Therapy, Unresectable Disease Becomes Resectable)
PROGRAM - DAY 1
THURSDAY 26 NOVEMBER 2026
Room: Federation Concert Hall
Chairs: TBA
| Perioperative therapies in Oesophagogastric Adenocarcinoma: Achievements and the Path Ahead | Oncology visitor |
| The evolving role of Radiotherapy in Oesophagogastric Adenocarcinoma: Standard, Selective, or Sunset? | Trevor Leong – Include TOPGEAR and learnings from TOPGEAR |
| Surgical status 2026 – multimodality management of oesophageal adenocarcinoma and how surgery is finding a new role | Surgical Visitor |
| Impact of nutritional status on oncological outcomes: How can we improve collaboration | Lisa Murnane |
Room: Federation Ballroom
Controversies and Debates: Evolving Perspectives and Emerging Consensus
Room: Federation Concert Hall
Chairs: TBA
| Can tailored or radical surgery make a crucial difference or is the die already cast by response to therapy? | Quality of surgery, and variation in practice - Surgical Speaker |
| The oligometastatic frontier: Defining “resectable stage IV” | Surgical Speaker |
| MDT case of oligometastatic disease | TBA |
| Peritoneal relapse in OG adenocarcinoma: OMECGA update, Are peritoneal-directed therapies ready for prime time? | TBA |
| Opportunities for AANZGOSA CTG Research a. Opportunities for GCT to interface with AANZGOSA – (CTG presenter) b. AANZGOSA research sub-committee – can this help the interface | a. CTG Presenter |
| Panel discussion: Opportunities and potential trials | Prof. Niall Tebbutt, Melbourne, Australia |
Room: Federation Ballroom
New Opportunities for Addressing Old Problems
Room: Federation Concert Hall
Chairs: TBA
| Immunotherapeutic Opportunities in dMMR Oesophagostric Adenocarcinoma | Oncology Visitor |
| IO – the Australian perspective | TBA |
| When immunotherapy reshapes the surgical battlefield: how and when to survey, modalities of response, when has a cCR been achieved? | TBA |
| Role of RTx and abscopal response | TBA |
| MDT case/Panel discussion |
Room: Federation Ballroom
Super MDT: Where guidelines meet reality
Room: Federation Concert Hall
Chairs: TBA
| SqCC – CRT, role of consolidation CRT, role of salvage surgery | TBA |
| Managing unresectable stage 3 disease | TBA |
| Stage IV with “extreme” response to induction | TBA |
Lumina (Part of the Tasman Hotel)
12 Murray Street, Hobart
Purchase a Dinner Ticket HERE
PROGRAM - DAY 2
FRIDAY 27 NOVEMBER 2026
Technical Precision the Challenging Oesophageal Dissection Post Radiotherapy (visitor/1 ANZ speaker/moderator/panel)
| Keynote introduction invited visitor surgical visitor: Translational research and its role in OG surgery | TBA |
| Key note oncology visitor: Neo-adjuvant therapy gastric cancer – immunotherapy and new directions | TBA |
| Volume performance relationship in ANZ: Have we improved and what should service delivery look like | TBA |
| Medical oncology centralised versus regional care | TBA |
| Delivering nutritional care and prehabilitation equitably what is the minimum standard of care? | TBA |
Looking to the Future
| Beyond the FLOT vs. CROSS Stalemate: trial data, real-world evidence and future directions | TBA - Med Oncologist |
| Where will be in 2030 and beyond in surgery for OG malignancy? | TBA |
| The patient who is physiological ‘borderline’ for surgery what to do. What if they improve during treatment? | TBA |
| Down staged disease what to do when does stage IV disease become resectable? | TBA |
| Credentialing for OG resections in ANZ what should it look like does AANZGOSA have a role to play | TBA |
Integrated Health
| TBA | |
| TBA | |
| TBA | |
| TBA | |
| TBA |
Complex Issues
| Key note lecture: Neuroendocrine tumours of the Upper GI tract | TBA |
| Key note lecture: Radical gastrectomy and what is XTG and how to do it? | TBA |
| Imaging in OG malignancy and staging: What is the latest and newest | TBA |
| Prehabilitation versus ERAS what is more important? | TBA |
| Patient and carer unmet needs | TBA |
AANZGOSA Free Papers
Collaboration Research and Multidisciplinary Care
| Part 1 - Complex gastric MDM – difficult cases e.g. Functional problems | TBA |
| Gastroparesis | TBA |
| Post bariatric surgery functional issues | TBA |
